Rosen Law Firm has issued deadline notices for securities class action lawsuits against Gossamer Bio, Upstart Holdings, and POET Technologies. Investors with losses exceeding $100K are encouraged to secure counsel before upcoming deadlines. The lawsuits allege false and misleading statements regarding clinical trial design and other material facts.

Rosen Law Firm is urging POET Technologies Inc. (NASDAQ: POET) investors who purchased securities between April 1, 2026 and April 27, 2026 to join a securities class action lawsuit. The lawsuit alleges that POET Technologies made false and misleading statements regarding its tax status as a potential passive foreign investment company (PFIC), failed to disclose negative tax implications for U.S. stockholders, and that a defendant violated a non-disclosure agreement by discussing business agreements publicly. The lead plaintiff deadline is June 29, 2026.

The Gross Law Firm has filed a securities class action lawsuit against POET Technologies Inc. for allegedly issuing materially false and misleading statements during April 1-27, 2026. The complaint alleges the company misrepresented its tax status as a potential passive foreign investment company, violated non-disclosure agreements by discussing business agreements publicly, and failed to disclose information that would negatively impact its valuation. Shareholders who purchased shares during the class period are encouraged to register by the June 29, 2026 deadline.

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against POET Technologies Inc. (NASDAQ: POET) for allegedly making false and misleading statements regarding its tax status as a potential passive foreign investment company (PFIC), failing to disclose negative tax implications for U.S. stockholders, and a violation of non-disclosure agreements by defendant Thomas Mika. The lead plaintiff deadline is June 29, 2026.

Rosen Law Firm is reminding investors who purchased POET Technologies securities between April 1-27, 2026 of a June 29, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that POET Technologies made false statements regarding its tax status as a potential passive foreign investment company (PFIC), failed to disclose negative tax implications for U.S. shareholders, and that a defendant violated a non-disclosure agreement by discussing business agreements publicly.

Poet Technologies stock fell 8.6% this week following the announcement of a $400 million fundraising deal involving the sale of approximately 19 million new shares to an institutional investor. Despite the pullback, the stock remains up 130.5% year-to-date. The sell-off reflects dilution concerns among investors, though the company continues its early-stage commercialization efforts with a $50 million order from Lumilens.

A securities fraud class action lawsuit has been filed against POET Technologies Inc. on behalf of investors who purchased shares between April 1-27, 2026. The lawsuit alleges the company misrepresented its tax status as a potential PFIC, and that CFO Thomas Mika violated confidentiality agreements by disclosing business information. The stock declined 8% on April 14 following a Wolfpack Research report about PFIC concerns, and dropped 47.4% on April 27 after the company announced cancellation of major purchase orders from Celestial AI/Marvell Semiconductor due to alleged disclosure violations.

Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against three companies: Regencell Bioscience Holdings (RGC) for alleged false statements regarding market manipulation vulnerability, SES AI Corporation (SES) for misrepresentations about business and growth prospects, and POET Technologies Inc. (POET) for alleged false disclosures regarding tax status. Investors who purchased shares during the specified periods and suffered losses are encouraged to seek legal representation.

Poet Technologies stock fell 8% on Tuesday as semiconductor stocks broadly pulled back due to macroeconomic and geopolitical concerns, profit-taking after recent rallies, and production concerns in the memory-chip market. The stock has been highly volatile following canceled orders from Marvell, a major order from Lumilens, and dilutive shareholder fundraising moves.

Poet Technologies stock fell 8.02% to $13.07 after completing a $400 million registered direct offering priced at $21 per share. While management capitalized on elevated stock prices to raise capital for AI photonic interconnect manufacturing, the offering sparked dilution concerns among existing shareholders. The broader market declined with the S&P 500 down 0.65% and Nasdaq down 0.84%.

Poet Technologies is developing optical interconnects for AI data centers with access to a potential $146 billion market opportunity by 2040. However, despite the massive addressable market and a $500 million deal with Lumilens, the company's stock is overvalued relative to its current $1.1 million in annual sales and early-stage commercialization status. Larger competitors like Broadcom, Cisco, and Marvell have entrenched positions that make it difficult for Poet to capture significant market share.

Robbins LLP filed a class action lawsuit against POET Technologies Inc. on behalf of investors who purchased securities between April 1-27, 2026. The lawsuit alleges that POET misrepresented its tax status as a passive foreign investment company (PFIC), which would negatively impact U.S. shareholders, and that an executive violated a non-disclosure agreement. The stock dropped following disclosure of these issues.